Green Cross, COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Rises 5.11% Up

On the 12th, the COVID-19 (plasma treatment/plasma therapeutics) theme rose by 3.11% compared to the previous day, showing strength, while Green Cross, a related stock drawing attention, surged by 5.11% compared to the previous day. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapeutics) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Green Cross's quant financial score was 27.2 points, ranking 6th in the quant financial ranking within the COVID-19 (plasma treatment/plasma therapeutics) related theme. This can be interpreted as Green Cross having relatively low investment attractiveness from a financial perspective. On the other hand, SMAC ranked 1st in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the robo algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.